Cargando…

Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease

BACKGROUND: There is increasing interest in improving understanding of the timing and nature of early neurodegeneration in Alzheimer’s disease (AD) and developing methods to measure this in vivo. Autosomal dominant familial Alzheimer’s disease (FAD) provides the opportunity for investigation of pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Weston, Philip S. J., Poole, Teresa, Nicholas, Jennifer M., Toussaint, Nicolas, Simpson, Ivor J. A., Modat, Marc, Ryan, Natalie S., Liang, Yuying, Rossor, Martin N., Schott, Jonathan M., Ourselin, Sebastien, Zhang, Hui, Fox, Nick C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499910/
https://www.ncbi.nlm.nih.gov/pubmed/32943095
http://dx.doi.org/10.1186/s13195-020-00679-2
_version_ 1783583759982919680
author Weston, Philip S. J.
Poole, Teresa
Nicholas, Jennifer M.
Toussaint, Nicolas
Simpson, Ivor J. A.
Modat, Marc
Ryan, Natalie S.
Liang, Yuying
Rossor, Martin N.
Schott, Jonathan M.
Ourselin, Sebastien
Zhang, Hui
Fox, Nick C.
author_facet Weston, Philip S. J.
Poole, Teresa
Nicholas, Jennifer M.
Toussaint, Nicolas
Simpson, Ivor J. A.
Modat, Marc
Ryan, Natalie S.
Liang, Yuying
Rossor, Martin N.
Schott, Jonathan M.
Ourselin, Sebastien
Zhang, Hui
Fox, Nick C.
author_sort Weston, Philip S. J.
collection PubMed
description BACKGROUND: There is increasing interest in improving understanding of the timing and nature of early neurodegeneration in Alzheimer’s disease (AD) and developing methods to measure this in vivo. Autosomal dominant familial Alzheimer’s disease (FAD) provides the opportunity for investigation of presymptomatic change. We assessed early microstructural breakdown of cortical grey matter in FAD with diffusion-weighted MRI. METHODS: Diffusion-weighted and T1-weighed MRI were acquired in 38 FAD mutation carriers (17 symptomatic, 21 presymptomatic) and 39 controls. Mean diffusivity (MD) was calculated for six cortical regions previously identified as being particularly vulnerable to FAD-related neurodegeneration. Linear regression compared MD between symptomatic and presymptomatic carriers and controls, adjusting for age and sex. Spearman coefficients assessed associations between cortical MD and cortical thickness. Spearman coefficients also assessed associations between cortical MD and estimated years to/from onset (EYO). Across mutation carriers, linear regression assessed associations between MD and EYO, adjusting for cortical thickness. RESULTS: Compared with controls, cortical MD was higher in symptomatic mutation carriers (mean ± SD CDR = 0.88 ± 0.39) for all six regions (p < 0.001). In late presymptomatic carriers (within 8.1 years of predicted symptom onset), MD was higher in the precuneus (p = 0.04) and inferior parietal cortex (p = 0.003) compared with controls. Across all presymptomatic carriers, MD in the precuneus correlated with EYO (p = 0.04). Across all mutation carriers, there was strong evidence (p < 0.001) of association between MD and cortical thickness in all regions except entorhinal cortex. After adjusting for cortical thickness, there remained an association (p < 0.05) in mutation carriers between MD and EYO in all regions except entorhinal cortex. CONCLUSIONS: Cortical MD measurement detects microstructural breakdown in presymptomatic FAD and correlates with proximity to symptom onset independently of cortical thickness. Cortical MD may thus be a feasible biomarker of early AD-related neurodegeneration, offering additional/complementary information to conventional MRI measures.
format Online
Article
Text
id pubmed-7499910
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74999102020-09-21 Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease Weston, Philip S. J. Poole, Teresa Nicholas, Jennifer M. Toussaint, Nicolas Simpson, Ivor J. A. Modat, Marc Ryan, Natalie S. Liang, Yuying Rossor, Martin N. Schott, Jonathan M. Ourselin, Sebastien Zhang, Hui Fox, Nick C. Alzheimers Res Ther Research BACKGROUND: There is increasing interest in improving understanding of the timing and nature of early neurodegeneration in Alzheimer’s disease (AD) and developing methods to measure this in vivo. Autosomal dominant familial Alzheimer’s disease (FAD) provides the opportunity for investigation of presymptomatic change. We assessed early microstructural breakdown of cortical grey matter in FAD with diffusion-weighted MRI. METHODS: Diffusion-weighted and T1-weighed MRI were acquired in 38 FAD mutation carriers (17 symptomatic, 21 presymptomatic) and 39 controls. Mean diffusivity (MD) was calculated for six cortical regions previously identified as being particularly vulnerable to FAD-related neurodegeneration. Linear regression compared MD between symptomatic and presymptomatic carriers and controls, adjusting for age and sex. Spearman coefficients assessed associations between cortical MD and cortical thickness. Spearman coefficients also assessed associations between cortical MD and estimated years to/from onset (EYO). Across mutation carriers, linear regression assessed associations between MD and EYO, adjusting for cortical thickness. RESULTS: Compared with controls, cortical MD was higher in symptomatic mutation carriers (mean ± SD CDR = 0.88 ± 0.39) for all six regions (p < 0.001). In late presymptomatic carriers (within 8.1 years of predicted symptom onset), MD was higher in the precuneus (p = 0.04) and inferior parietal cortex (p = 0.003) compared with controls. Across all presymptomatic carriers, MD in the precuneus correlated with EYO (p = 0.04). Across all mutation carriers, there was strong evidence (p < 0.001) of association between MD and cortical thickness in all regions except entorhinal cortex. After adjusting for cortical thickness, there remained an association (p < 0.05) in mutation carriers between MD and EYO in all regions except entorhinal cortex. CONCLUSIONS: Cortical MD measurement detects microstructural breakdown in presymptomatic FAD and correlates with proximity to symptom onset independently of cortical thickness. Cortical MD may thus be a feasible biomarker of early AD-related neurodegeneration, offering additional/complementary information to conventional MRI measures. BioMed Central 2020-09-17 /pmc/articles/PMC7499910/ /pubmed/32943095 http://dx.doi.org/10.1186/s13195-020-00679-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Weston, Philip S. J.
Poole, Teresa
Nicholas, Jennifer M.
Toussaint, Nicolas
Simpson, Ivor J. A.
Modat, Marc
Ryan, Natalie S.
Liang, Yuying
Rossor, Martin N.
Schott, Jonathan M.
Ourselin, Sebastien
Zhang, Hui
Fox, Nick C.
Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease
title Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease
title_full Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease
title_fullStr Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease
title_full_unstemmed Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease
title_short Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease
title_sort measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499910/
https://www.ncbi.nlm.nih.gov/pubmed/32943095
http://dx.doi.org/10.1186/s13195-020-00679-2
work_keys_str_mv AT westonphilipsj measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT pooleteresa measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT nicholasjenniferm measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT toussaintnicolas measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT simpsonivorja measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT modatmarc measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT ryannatalies measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT liangyuying measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT rossormartinn measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT schottjonathanm measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT ourselinsebastien measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT zhanghui measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease
AT foxnickc measuringcorticalmeandiffusivitytoassessearlymicrostructuralcorticalchangeinpresymptomaticfamilialalzheimersdisease